TrialJapanese journal of clinical oncology2026
Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo).
Norifumi Hattori et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.